Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.
Identifieur interne : 002624 ( PubMed/Corpus ); précédent : 002623; suivant : 002625Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.
Auteurs : Sagar U. Kapadia ; John K. Rose ; Elaine Lamirande ; Leatrice Vogel ; Kanta Subbarao ; Anjeanette RobertsSource :
- Virology [ 0042-6822 ] ; 2005.
English descriptors
- KwdEn :
- Animals, Antibody Formation, Cell Line, Cricetinae, DNA Primers, Immunity, Cellular, Kidney, Mice, Reverse Transcriptase Polymerase Chain Reaction, SARS Virus (genetics), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Vaccines, Attenuated, Vaccines, DNA, Vesicular stomatitis Indiana virus (immunology), Viral Vaccines.
- MESH :
- chemical : DNA Primers, Vaccines, Attenuated, Vaccines, DNA, Viral Vaccines.
- genetics : SARS Virus.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome, Vesicular stomatitis Indiana virus.
- Animals, Antibody Formation, Cell Line, Cricetinae, Immunity, Cellular, Kidney, Mice, Reverse Transcriptase Polymerase Chain Reaction.
Abstract
Although the recent SARS coronavirus (SARS-CoV) that appeared in 2002 has now been contained, the possibility of re-emergence of SARS-CoV remains. Due to the threat of re-emergence, the overall fatality rate of approximately 10%, and the rapid dispersion of the virus via international travel, viable vaccine candidates providing protection from SARS are clearly needed. We developed an attenuated VSV recombinant (VSV-S) expressing the SARS coronavirus (SARS-CoV) spike (S) protein. In cells infected with this recombinant, S protein was synthesized, glycosylated at approximately 17 Asn residues, and transported via the Golgi to the cell surface. Mice vaccinated with VSV-S developed SARS-neutralizing antibody and were able to control a challenge with SARS-CoV performed at 1 month or 4 months after a single vaccination. We also demonstrated, by passive antibody transfer, that the antibody response induced by the vaccine was sufficient for controlling SARS-CoV infection. A VSV-vectored SARS vaccine could have significant advantages over other SARS vaccine candidates described to date.
DOI: 10.1016/j.virol.2005.06.016
PubMed: 16043204
Links to Exploration step
pubmed:16043204Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.</title><author><name sortKey="Kapadia, Sagar U" sort="Kapadia, Sagar U" uniqKey="Kapadia S" first="Sagar U" last="Kapadia">Sagar U. Kapadia</name><affiliation><nlm:affiliation>Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Rose, John K" sort="Rose, John K" uniqKey="Rose J" first="John K" last="Rose">John K. Rose</name></author><author><name sortKey="Lamirande, Elaine" sort="Lamirande, Elaine" uniqKey="Lamirande E" first="Elaine" last="Lamirande">Elaine Lamirande</name></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16043204</idno><idno type="pmid">16043204</idno><idno type="doi">10.1016/j.virol.2005.06.016</idno><idno type="wicri:Area/PubMed/Corpus">002624</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002624</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.</title><author><name sortKey="Kapadia, Sagar U" sort="Kapadia, Sagar U" uniqKey="Kapadia S" first="Sagar U" last="Kapadia">Sagar U. Kapadia</name><affiliation><nlm:affiliation>Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Rose, John K" sort="Rose, John K" uniqKey="Rose J" first="John K" last="Rose">John K. Rose</name></author><author><name sortKey="Lamirande, Elaine" sort="Lamirande, Elaine" uniqKey="Lamirande E" first="Elaine" last="Lamirande">Elaine Lamirande</name></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name></author></analytic><series><title level="j">Virology</title><idno type="ISSN">0042-6822</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibody Formation</term><term>Cell Line</term><term>Cricetinae</term><term>DNA Primers</term><term>Immunity, Cellular</term><term>Kidney</term><term>Mice</term><term>Reverse Transcriptase Polymerase Chain Reaction</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Vaccines, Attenuated</term><term>Vaccines, DNA</term><term>Vesicular stomatitis Indiana virus (immunology)</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>DNA Primers</term><term>Vaccines, Attenuated</term><term>Vaccines, DNA</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Vesicular stomatitis Indiana virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Antibody Formation</term><term>Cell Line</term><term>Cricetinae</term><term>Immunity, Cellular</term><term>Kidney</term><term>Mice</term><term>Reverse Transcriptase Polymerase Chain Reaction</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although the recent SARS coronavirus (SARS-CoV) that appeared in 2002 has now been contained, the possibility of re-emergence of SARS-CoV remains. Due to the threat of re-emergence, the overall fatality rate of approximately 10%, and the rapid dispersion of the virus via international travel, viable vaccine candidates providing protection from SARS are clearly needed. We developed an attenuated VSV recombinant (VSV-S) expressing the SARS coronavirus (SARS-CoV) spike (S) protein. In cells infected with this recombinant, S protein was synthesized, glycosylated at approximately 17 Asn residues, and transported via the Golgi to the cell surface. Mice vaccinated with VSV-S developed SARS-neutralizing antibody and were able to control a challenge with SARS-CoV performed at 1 month or 4 months after a single vaccination. We also demonstrated, by passive antibody transfer, that the antibody response induced by the vaccine was sufficient for controlling SARS-CoV infection. A VSV-vectored SARS vaccine could have significant advantages over other SARS vaccine candidates described to date.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16043204</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0042-6822</ISSN><JournalIssue CitedMedium="Print"><Volume>340</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Virology</Title><ISOAbbreviation>Virology</ISOAbbreviation></Journal><ArticleTitle>Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.</ArticleTitle><Pagination><MedlinePgn>174-82</MedlinePgn></Pagination><Abstract><AbstractText>Although the recent SARS coronavirus (SARS-CoV) that appeared in 2002 has now been contained, the possibility of re-emergence of SARS-CoV remains. Due to the threat of re-emergence, the overall fatality rate of approximately 10%, and the rapid dispersion of the virus via international travel, viable vaccine candidates providing protection from SARS are clearly needed. We developed an attenuated VSV recombinant (VSV-S) expressing the SARS coronavirus (SARS-CoV) spike (S) protein. In cells infected with this recombinant, S protein was synthesized, glycosylated at approximately 17 Asn residues, and transported via the Golgi to the cell surface. Mice vaccinated with VSV-S developed SARS-neutralizing antibody and were able to control a challenge with SARS-CoV performed at 1 month or 4 months after a single vaccination. We also demonstrated, by passive antibody transfer, that the antibody response induced by the vaccine was sufficient for controlling SARS-CoV infection. A VSV-vectored SARS vaccine could have significant advantages over other SARS vaccine candidates described to date.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Sagar U</ForeName><Initials>SU</Initials><AffiliationInfo><Affiliation>Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>John K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Lamirande</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Leatrice</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Subbarao</LastName><ForeName>Kanta</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Anjeanette</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 AI057158</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI057158</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Virology</MedlineTA><NlmUniqueID>0110674</NlmUniqueID><ISSNLinking>0042-6822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014721" MajorTopicYN="N">Vesicular stomatitis Indiana virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>06</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16043204</ArticleId><ArticleId IdType="pii">S0042-6822(05)00356-9</ArticleId><ArticleId IdType="doi">10.1016/j.virol.2005.06.016</ArticleId><ArticleId IdType="pmc">PMC7111745</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Lett. 2004 Sep;95(2):139-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15388253</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 May;74(10):4652-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10775601</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1990 Mar;64(3):1407-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2154621</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Jan 4;23(7):924-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15603894</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1999 May;73(5):3723-32</Citation><ArticleIdList><ArticleId IdType="pubmed">10196265</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Mar;78(6):3196-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14990742</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Chin Med J (Engl). 2004 Nov;117(11):1625-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15569476</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>DNA Cell Biol. 2004 Jun;23(6):391-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15231072</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>AIDS Res Hum Retroviruses. 2004 Sep;20(9):989-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">15585086</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2003 Nov 15;171(10):4969-73</Citation><ArticleIdList><ArticleId IdType="pubmed">14607890</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jul 2;319(3):746-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15184046</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1998 Jun;72(6):4704-11</Citation><ArticleIdList><ArticleId IdType="pubmed">9573234</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15150417</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int Immunol. 2004 Oct;16(10):1423-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15314040</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arch Virol. 1994;138(1-2):117-34</Citation><ArticleIdList><ArticleId IdType="pubmed">7980002</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Nov;83(21):8122-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3095828</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation><ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15748-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15496474</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Nov;78(22):12672-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15507655</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2273-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15755610</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2001 Nov;75(22):11079-87</Citation><ArticleIdList><ArticleId IdType="pubmed">11602747</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1996 Apr;70(4):2318-23</Citation><ArticleIdList><ArticleId IdType="pubmed">8642658</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1992 Nov;66(11):6502-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1383566</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 1993 Oct;74 ( Pt 10):2061-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8409930</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1996 May 1;156(9):3342-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8617959</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S88-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15577937</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell. 2001 Sep 7;106(5):539-49</Citation><ArticleIdList><ArticleId IdType="pubmed">11551502</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1995 May 9;92(10):4477-81</Citation><ArticleIdList><ArticleId IdType="pubmed">7753828</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15530413</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002624 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002624 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16043204
|texte= Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16043204" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |